drugset / Trial / NCT05347979
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
Timeline
- Start
- 2022-05-25
- Primary completion
- 2022-07-19
- Completion
- 2022-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 75 mg | Oral |
| Subject | Relacorilant | Small molecule | 400 mg | Oral |